Disclaimer: Whilst we always aim to provide accurate information, Recite Me uses machine translation so the translation may not be perfect and we can’t guarantee its accuracy. Myeloma UK accepts no liability for any inaccuracies resulting from the use of this translation tool. The information provided is not meant to replace the advice of your healthcare team. Find out more about this tool at reciteme.com
For HCPs working in myeloma, the programme covers key areas of current practice and emerging change, including treatment for newly diagnosed myeloma, risk and MRD stratification, and the growing role of bispecifics and CAR-T for relapsed and refractory myeloma.
The myeloma programme includes
Updates on newly diagnosed treatment approaches, including risk and MRD stratification, with Dr Jaimal Kothari
Bispecific and CAR-T treatment for relapsed and refractory myeloma with Professor Martin Kaiser
Discussion: changing landscape for the UK, led by Dr Rakesh Popat
This makes it a relevant event for consultants, trainees, nurses, pharmacists, and other HCPs involved in myeloma treatment and service planning.
–
